146 Articles with the topic: Pharma & Medical Industry News
Testicles could provide "ethical" stem cells
sea-maid submitted, created time 1 month 6 days (www.newscientist.com)
This article provides more information about last week's announcement that researchers have found a form of adult stem cells that appear to be as versatile as embryonic cells ...in men's testicles.
A team out of the University of Tubingen in Germany managed to convert spermatagonial cells into skin, gut structures, cartilage, bone, muscle, and neurons, quite an accomplishment. Some of their colleagues are enthusiastic. Robert Lanza of Advanced Cell Technology in Massachusetts (U.S 
NIH Suspends Grant to Emory University
jerry submitted, created time 1 month 5 days (sciencenow.sciencemag.org)
The National Institutes of Health (NIH) has suspended a $9 million grant for a depression study led by psychiatrist Charles Nemeroff at Emory University in Atlanta. The punishment, imposed in August but only made public today, is apparently the most severe reaction by NIH so far to a Senate investigation of NIH-funded researchers who may have failed to report all of their income from drug companies.
Recipients of NIH grants are required to report income from industry consulting activities
Should healthy people take statins too?
sea-maid submitted, created time 4 days 8 hours (www.nature.com)
The results of a study examining whether a potent cholesterol-lowering drug decreases the risk of heart disease are out. Rosuvastatin was given to 17,802 seemingly healthy people, and their chance of developing heart problems plummeted. The results, published in the New England Journal of Medicine, have revealed a number of questions about how to prevent heart attacks. Is exercise and a low-fat diet enough, or should large swathes of the population be prescribed preventative medication? Nature News gets to the heart of the matter.
Ginkgo Biloba Does Not Reduce Dementia Risk, Study Shows
piggy submitted, created time 2 days 9 minutes (www.sciencedaily.com)
The medicinal herb Ginkgo biloba does not reduce the risk of dementia or Alzheimer's disease development in either the healthy elderly or those with mild cognitive impairment, according to a large multicenter trial led by researchers at the University of Pittsburgh School of Medicine.
Findings from the Ginkgo Evaluation of Memory (GEM) Study, which is the first to have the necessary participant numbers and monitoring years to enable measurement of G. biloba's effectiveness and safety profile in dementia prevention, were just published in the Journal of the American Medical Association
Dozens of patent decisions may be overturned!
Darkfrog submitted, created time 6 months 1 week (www.nytimes.com)
A professor at George Washington University--not one of us this time; he's a law professor--has brought to light some shades of U.S. law that suggest that the appointments of forty-six judges may have been unconstitutional. What does that mean for scientists? Well, these judges laid down decisions for the U.S. Patent and Trademark Office, both deciding whether patents should be issued for new inventions and resolving patent disputes.
If the appointments are declared unconstitutional, then who knows how many decisions may be overturned? The translogic decision alone was worth $86 million.
Ark floats gene therapy's boat, for now
sea-maid submitted, created time 3 weeks 5 days (www.nature.com)
In August, gene therapy's turbulent ride through the clinical rapids took a new twist as Ark Therapeutics released positive top-line results from a phase 3 trial of its adenoviral gene therapy Cerepro (sitimagene ceradenovec) for malignant brain tumors. Although the news boosted the London-based firm's shares, the course to market authorization and registration remains strewn with uncertainty—as Introgen, of Austin, Texas, found, to its cost, when the U.S
GlaxoSmithKline's customized "red wine" drug potent in mice
piggy submitted, created time 2 weeks 20 hours (www.reuters.com)
LONDON (Reuters) - A drug in development that mimics a health-boosting compound found in red wine may be a powerful weapon in the fight against obesity and diabetes, researchers said on Tuesday.
A study of mice showed that the GlaxoSmithKline drug SRT1720 was about a thousand times more potent than resveratrol in activating an enzyme that helped the animals burn more energy and lower their insulin and glucose levels
Direct Genetic Analysis of Single Cancer Cells for Therapy Selection in Cancer
jerry submitted, created time 6 months 1 week (www.cancercell.org)
The increasing use of primary tumors as surrogate markers for prognosis and therapeutic decisions neglects evolutionary aspects of cancer progression.
The reseachers identified chromosome 17q12–21, the region comprising HER2, as the most frequent gain in disseminated tumor cells that were isolated from both ectopic sites when they analyzed single disseminated cancer cells from lymph nodes and bone marrow of 107 consecutive esophageal cancer patients.
Stopping clinical trials early
sea-maid submitted, created time 5 months 2 weeks (www.bmj.com)
Should we be worried about an apparent rise in the number of clinical trials now being stopped early because the results are so good? Margaret McCartney asks how convincing should results be before trials are halted - and what the implications are for patients.
Stem cell treatment leaves boy with recessive epidermolysis bullosa improving daily
Darkfrog submitted, created time 5 months 1 week (www.latimes.com)
Two-year-old Nate Liao is eating solid food, playing with his sibs and generally running around and getting into things. The reason? His body has started producing collagen VII, the material that anchor's a person's skin to the rest of his body. Before he was treated, the least contact could cause bruising and blisters. Eating anything non-liquid could tear the lining of his esophagus.
Some of Nate's doctors are suggesting that epidermolysis bullosa be taken "off the incurable list." Little Nate was given a mixture of bone marrow and cord blood stem cells
sea-maid submitted, created time 3 weeks 4 days (www.fiercebiotech.com)
Pacgen Biopharmaceuticals Corporation ("Pacgen" or the "Company") (TSX VENTURE: PGA) announced today that it has entered into a letter of intent for a business combination with Medigen Biotechnology Corp. ("Medigen"), a biotech company traded over the bulletin board in Taiwan. In connection with the transaction, Pacgen would acquire all of the issued and outstanding shares of Medigen by way of share purchase or through such other transaction structure as may be determined by the mutual agreement of Medigen and Pacgen
BioTie Therapies Inc. to Acquire Neurology and Immunology Focused Pharmaceutical Company Elbion GmbH
sea-maid submitted, created time 3 weeks 4 days (www.fiercebiotech.com)
BioTie Therapies has today entered into an agreement to acquire the German pharmaceutical company elbion GmbH. The combination of the two businesses will take place by a share exchange and create a leading European company in the field of discovery and development of therapeutics for central nervous system (addiction, psychotic disorders) and inflammatory diseases (e.g. rheumatoid arthritis, psoriasis and inflammatory diseseas of the respiratory system). elbion GmbH will become a wholly-owned subsidiary of BioTie.
HIV vaccine failure explained?
sea-maid submitted, created time 2 weeks 1 day (www.nature.com)
Researchers have suggested that an experimental vaccine against AIDS might have failed in part because it made some people's immune cells more vulnerable to HIV infection.
Pfizer ends development of obesity drug
piggy submitted, created time 2 weeks 2 hours (www.reuters.com)
NEW YORK, Nov 5 (Reuters) - Pfizer Inc on Wednesday became the latest drugmaker to abandon an obesity treatment that works by blocking the receptors in the brain that makes people hungry after smoking marijuana.
The world's largest drugmaker said it was terminating late stage development of its experimental obesity drug, CP-945,598, citing a more conservative regulatory climate and problems seen with other medicines from the same class
Industry shifts focus to immunology and cancer
sea-maid submitted, created time 1 week 3 days (www.nature.com)
Economic factors, including competition from generic drugs, is hitting even the big pharmaceutical companies hard, reports Nature. In 2010, Pfizer's Lipitor enters the public domain. For these reasons, the larger companies are narrowing the focus of their research, hitting fewer diseases. They're also working on fewer primary care drugs and more drugs that would be prescribed by specialists, such as cancer drugs.
"When Wyeth Pharmaceuticals announced last week that it would cut some of its research and development (R&D) programs in women's health, the decision seemed counterintuitive
abuse@discover8.com
angelfish
kavin
Sue Wu
jane2007
DanyC
addict
Anti V5-tag polyclonal antibody is developed in goat using a ...
www.genscript.com
Express PAGE Gel
Gels: Express PAGE Gel
www.genscript.com
Western Optimization Customized Kit (Mouse PS A-b)
Kit : Western Optimization Customized Kit (Mouse PS A-b) ...
www.genscript.com
Rabbit Anti eIF2α (Ab-51) (polyclonal)
antibody : Rabbit Anti eIF2α (Ab-51) (polyclonal) ...
www.genscript.com